Please wait while the transcript is being prepared...
0:00
ANJE A. TE VELDE, PHD: Hello.
My name is Anje te Velde.
I am a TI at the
Tytgat Institute for
Liver and Intestinal
Research in Amsterdam.
0:08
During this talk I
will introduce you
to the inflammatory bowel diseases.
In short, IBD.
Then I will give an
overview of the different
experimental colitis models
that are currently used.
The field of IBD research
has had great benefits
from these experimental
colitis models
in the understanding of the
pathogenesis of the disease.
We have learned a great
deal from these models
about the involvement of
genetics, the microbiota,
and the role of different cells
in the development of the disease.
Finally, I will give some
guidance to the decision-making
of which model to choose
for your experiments.
0:46
IBD covers two types of chronic
intestinal inflammation:
Crohn's disease and
Ulcerative Colitis.
Patients suffer from chronic
relapsing intestinal inflammation
leading to abdominal pain, bloody
diarrhea, weight loss, and fatigue.
Most patients are diagnosed
between their second
and fourth decade of life.
Patients need chronic
medical treatments.
However, refractoriness and loss
of response are major problems.
Characteristically, Crohn's disease can
affect entire gastrointestinal tracts,
resulting in discontinuous
transmural ulcers,
mainly in the terminal ilium
and right-sided large intestine.
Ulcerative colitis
continuously affects
the mucosa of the large intestine.
1:34
In the mucosa, there's the tight
regulation of the immune response,
characterized in
the normal situation
by a balance between a sufficient
response to potential pathogens,
and no response to
nonpathogenic commensal bacteria
and compounds of the diet.
